Eton Pharmaceuticals (ETON) Cost of Revenue (2019 - 2026)

Eton Pharmaceuticals has disclosed Cost of Revenue across 8 years of filings, most recently posting $12.2 million for Q2 2026.

• In Q2 2026, Cost of Revenue rose 73.84% year-over-year to $12.2 million; the TTM figure through Jun 2026 stood at $42.0 million (up 77.68% YoY), while the FY2025 annual figure was $37.2 million, up 138.53% from the prior year.
• Cost of Revenue came in at $12.2 million for Q2 2026 at Eton Pharmaceuticals, up from $8.2 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $14.6 million in Q3 2025 to a low of $849000.0 in Q1 2022.
• Average Cost of Revenue over 5 years is $4.9 million, with a median of $3.4 million recorded in 2024.
• The largest YoY upside for Cost of Revenue was 1477.59% in 2022 against a maximum downside of 46.6% in 2022.
• Over 5 years, Cost of Revenue stood at $2.1 million in 2022, then jumped by 72.26% to $3.7 million in 2023, then jumped by 40.4% to $5.2 million in 2024, then soared by 58.21% to $8.2 million in 2025, then surged by 48.83% to $12.2 million in 2026.
• Per Business Quant data, the three most recent Cost of Revenue figures were $12.2 million in Q2 2026, $8.2 million in Q4 2025, and $14.6 million in Q3 2025.